Notably, studies from the last five years have demonstrated that paclitaxel significantly inhibits the migration of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) and reduces the production of critical inflammatory mediators, including IL-6, IL-8, and IL-1β [49]. Here, IL1B is linked to rheumatoid arthritis.